Transforming life for people living with Parkinson’s and other CNS disorders

Transforming life for people living with Parkinson’s and other CNS disorders

LATEST PRESS RELEASES
OCTOBER 2, 2025

IRLAB progresses fully funded IRL757 study in Parkinson’s Disease in partnership with MSRD

Gothenburg, Sweden, October 2, 2025 – IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), a company discovering and developing novel treatments for Parkinson’s disease, today announced that its collaborator, – the McQuade Center for Strategic Research and Development, LLC (MSRD) – has issued a payment of USD 4 million to further advance the drug candidate IRL757 into a clinical safety, tolerability and Signal Finding Study in patients with Parkinson’s disease who experience apathy. The first patients are expected to be enrolled before the end of 2025.

Read More >

IRLAB carries out SEK 136m rights issue

IRLAB A
2.92
SEK
TODAY
0.34 %
TODAY SEK
0.01 SEK
15:29:49
2025-10-02
More share info >

ISP – The proprietary technology platform

IRLAB’s unique and resource efficient research method, the Integrative Screening Process (ISP), generates the company’s drug pipeline. This proprietary platform is built on a systems pharmacology discovery approach with an extensive, world unique, standardized database on CNS compounds and classes collected over 25 years.

IRLAB’s clinical phase II candidates

Mesdopetam (IRL790)

In development to treat levodopa-induced dyskinesia (LIDs), i.e. involuntary movements occurring upon long-term treatment with levodopa in Parkinson’s disease.  

Pirepemat (IRL752)

In development to treat impaired balance (postural dysfunction) leading to falls in Parkinson’s disease.

LATEST PRESENTATION
JUNE 10, 2025

Presentation by Kristina Torfgård, CEO, at Aktiespararna

Presentation by Kristina Torfgård, CEO, at Aktiespararna (in Swedish), held June 10, 2025.

Read More >